Please use this identifier to cite or link to this item:
|Title:||Understanding cardiac biomarkers in end-stage kidney disease: Frequently asked questions and the promise of clinical application.|
|Authors:||Roberts, Matthew A;Hedley, Adam J;Ierino, Francesco L|
|Affiliation:||Department of Nephrology, Austin Health Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia. firstname.lastname@example.org|
|Citation:||Nephrology (carlton, Vic.); 16(3): 251-60|
|Abstract:||A novel strategy in the management of cardiovascular disease in patients with end-stage kidney disease is the use of biochemical markers to facilitate the detection of cardiovascular abnormalities in the hope that this will allow effective therapy to be instituted earlier. The cardiac troponins and B-type natriuretic peptide are among the best studied of these biochemical markers of cardiovascular disease. However, controversy remains regarding the interpretation of such results and the subsequent clinical application of these biomarkers, particularly when abnormal in patients with end-stage kidney disease. This review addresses some of the important issues to consider with the interpretation of abnormal cardiac troponin and B-type natriuretic peptide results in patients undergoing dialysis.|
|Internal ID Number:||21342319|
Kidney Failure, Chronic.blood.complications.therapy
Natriuretic Peptide, Brain.blood
Predictive Value of Tests
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.